The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Body mass index and survival of patients with metastastic renal cell carcinoma: Data from the German prospective RCC registry.
Lothar Mueller
No relevant relationships to disclose
Peter J. Goebell
Consultant or Advisory Role - Amgen; Bayer; Consultant/Advisory role; GlaxoSmithKline; Janssen-Cilag; Novartis; Roche; Sanofi
Honoraria - Bayer; Bristol-Myers Squibb; GlaxoSmithKline; HONORARIA; Janssen-Cilag; Novartis; Pfizer; Roche; Sanofi
Ulla Von Verschuer
No relevant relationships to disclose
Hans-Juergen Hurtz
No relevant relationships to disclose
Melanie Franzem
Employment or Leadership Position - iOMEDICO
Michele Vogt
Employment or Leadership Position - iOMEDICO
Norbert Marschner
Employment or Leadership Position - iOMEDICO
Stock Ownership - iOMEDICO (B)